Promising Cancer Treatments: Lung and Rectal Cancer Patients See Positive Results in Studies.
Originally Published 2 years ago — by The Guardian
A daily pill called osimertinib has been found to reduce the risk of dying from lung cancer by 51%, according to a decade-long global study. The Adaura trial involved patients aged between 30 and 86 in 26 countries and looked at whether the pill could help non-small cell lung cancer patients, the most common form of the disease. Everyone in the trial had a mutation of the EGFR gene, which is found in about a quarter of global lung cancer cases, and accounts for as many as 40% of cases in Asia. The pill was proven to be “practice-changing” and should become the “standard of care” for the quarter of lung cancer patients worldwide with the EGFR mutation.